NCT03775538View on ClinicalTrials.gov

Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 5, 2018

Primary Completion Date

July 8, 2020

Study Completion Date

July 8, 2020

Conditions
Parkinson DiseaseMovement DisordersNeuro-Degenerative DiseaseNervous System DiseasesBrain Diseases
Interventions
DRUG

Cerebral Dopamine Neurotrophic Factor

Repeated intracerebral infusions

DEVICE

Renishaw Drug Delivery System

Stereotactically implanted device

Trial Locations (3)

14186

Karolinska University Hospital, Stockholm

00029

Helsinki University Hospital, Helsinki

221 85

Skåne University Hospital, Lund

Sponsors
All Listed Sponsors
collaborator

Renishaw plc.

UNKNOWN

lead

Herantis Pharma Plc.

INDUSTRY

NCT03775538 - Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study | Biotech Hunter | Biotech Hunter